首页> 美国卫生研究院文献>Journal of Clinical Microbiology >Imported Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae Clones in a Greek Hospital: Impact of Infection Control Measures for Restraining Their Dissemination
【2h】

Imported Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae Clones in a Greek Hospital: Impact of Infection Control Measures for Restraining Their Dissemination

机译:一家希腊医院中进口的肺炎克雷伯菌肺炎克雷伯菌酶生产的肺炎克雷伯菌克隆:感染控制措施对其传播的抑制作用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The recent emergence of carbapenemase-producing Enterobacteriaceae strains represents a major threat for hospitalized patients. We document the dissemination and control of carbapenemase-producing Klebsiella pneumoniae clones in a Greek hospital. During a 3-year study period (January 2009 to December 2011), carbapenemase-producing K. pneumoniae strains were isolated from clinical samples from 73 individual patients. Phenotyping and molecular testing confirmed that 52 patients were infected with K. pneumoniae carbapenemase 2 (KPC-2) producers, 12 were infected with VIM-1 producers, and the remaining 9 were infected with isolates producing both KPC-2 and VIM-1 enzymes. Twenty-eight of these clinical cases were characterized as imported health care associated, and 23 of these were attributed to KPC producers and 5 were attributed to KPC and VIM producers. The remaining 45 cases were deemed hospital acquired. In the second year of the study, intensified infection control intervention was implemented, followed by active surveillance and carrier isolation in the third year. The incidence of carbapenemase-producing K. pneumoniae patient cases decreased from 0.52/1,000 patient days in 2009 to 0.32/1,000 patient days in 2010 (P = 0.075). Following these additional infection control measures, the incidence fell to 0.21/1,000 patient days in 2011 and differed significantly from that in 2009 (P = 0.0028). Despite the fact that the imported cases of carbapenemase-producing K. pneumoniae were equally distributed over this 3-year period, the incidence of hospital-acquired cases decreased from 0.36/1,000 patient days in 2009 to 0.19/1,000 patient days in 2010 (P = 0.058) and to 0.1/1,000 patient days in 2011 (P = 0.0012). Our findings suggest that rigorous infection control measures and active surveillance can effectively reduce the incidence of secondary transmission due to KPC-producing pathogens.
机译:产生碳青霉烯酶的肠杆菌科菌株的最新出现对住院患者构成了重大威胁。我们在希腊一家医院记录了碳青霉烯酶生产性肺炎克雷伯菌的传播和控制。在为期3年的研究期内(2009年1月至2011年12月),从73例患者的临床样本中分离出了产生碳青霉烯酶的肺炎克雷伯菌菌株。表型和分子测试证实52例患者感染了肺炎克雷伯菌碳青霉烯酶2(KPC-2)产生者,12例感染了VIM-1产生者,其余9例感染了同时产生KPC-2和VIM-1酶的分离株。这些临床病例中有28个被定为与进口卫生保健有关,其中23个归因于KPC生产者,其中5个归因于KPC和VIM生产者。其余45例被认为是医院获得的。在研究的第二年,实施了强化的感染控制干预措施,随后在第三年进行了主动监测和携带者隔离。产生碳青霉烯酶的肺炎克雷伯菌患者的发病率从2009年的0.52 / 1,000患者日减少到2010年的0.32 / 1,000患者日(P = 0.075)。在采取了这些额外的感染控制措施之后,该发病率在2011年降至0.21 / 1,000患者日,与2009年相比有显着差异(P = 0.0028)。尽管在这3年期间进口了产生碳青霉烯酶的肺炎克雷伯菌的病例分布均等,但医院获得病例的发生率从2009年的0.36 / 1,000患者日减少到2010年的0.19 / 1,000患者日(P = 0.058),2011年为0.1 / 1,000患者日(P = 0.0012)。我们的发现表明,严格的感染控制措施和积极的监测可以有效地减少由于产生KPC的病原体引起的二次传播的发生。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号